153 related articles for article (PubMed ID: 19646479)
21. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.
Su C; Cao H; Tan S; Huang Y; Jia X; Jiang L; Wang K; Chen Y; Long J; Liu X; Wu M; Wu X; Qian Q
Toxicol Sci; 2008 Nov; 106(1):242-50. PubMed ID: 18703561
[TBL] [Abstract][Full Text] [Related]
22. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
23. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
Bilsland AE; Merron A; Vassaux G; Keith WN
Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167
[TBL] [Abstract][Full Text] [Related]
24. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site.
Carette JE; Graat HC; Schagen FH; Abou El Hassan MA; Gerritsen WR; van Beusechem VW
J Gene Med; 2005 Aug; 7(8):1053-62. PubMed ID: 15756711
[TBL] [Abstract][Full Text] [Related]
25. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
Lanson NA; Friedlander PL; Schwarzenberger P; Kolls JK; Wang G
Cancer Res; 2003 Nov; 63(22):7936-41. PubMed ID: 14633724
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
[TBL] [Abstract][Full Text] [Related]
27. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
Xie M; Niu JH; Chang Y; Qian QJ; Wu HP; Li LF; Zhang Y; Li JL; Huang XJ; Ruan GR
Apoptosis; 2009 Sep; 14(9):1086-94. PubMed ID: 19551515
[TBL] [Abstract][Full Text] [Related]
28. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter.
Shi CX; Graham FL; Hitt MM
J Gene Med; 2006 Apr; 8(4):442-51. PubMed ID: 16389604
[TBL] [Abstract][Full Text] [Related]
29. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
30. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
31. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression.
Jin F; Kretschmer PJ; Hermiston TW
Mol Ther; 2005 Dec; 12(6):1052-63. PubMed ID: 16165398
[TBL] [Abstract][Full Text] [Related]
33. Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region.
Danielsson A; Dzojic H; Nilsson B; Essand M
Cancer Gene Ther; 2008 Apr; 15(4):203-13. PubMed ID: 18188185
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
36. High efficient generation of replication-defective adenoviruses containing thymidine kinase by homogeneous recombination in bacteria.
Cong TC; Lu ZM; Li Y; Zheng L; Qin Y
Chin Med J (Engl); 2007 Sep; 120(18):1622-5. PubMed ID: 17908483
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
Kim J; Cho JY; Kim JH; Jung KC; Yun CO
Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.
Robinson M; Ge Y; Ko D; Yendluri S; Laflamme G; Hawkins L; Jooss K
Cancer Gene Ther; 2008 Jan; 15(1):9-17. PubMed ID: 17853920
[TBL] [Abstract][Full Text] [Related]
39. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma.
Hannay J; Davis JJ; Yu D; Liu J; Fang B; Pollock RE; Lev D
Gene Ther; 2007 Apr; 14(8):671-81. PubMed ID: 17287860
[TBL] [Abstract][Full Text] [Related]
40. Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3.
Zhao Y; Li H; Wu R; Li S; Wang P; Wang H; Wang J; Zhou J
PLoS One; 2015; 10(5):e0126726. PubMed ID: 25978371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]